" class="no-js "lang="en-US"> Twist Bioscience and Ginkgo Bioworks Sign New Collaboration - Medtech Alert
Friday, March 29, 2024

Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement includes an increased commitment by Ginkgo to purchase products from Twist, with the option to access significantly more synthesis capacity to meet Ginkgo’s anticipated growth. The partnership builds on a previous supply agreement signed in 2017.

“We love to make investments alongside incredible partners like Twist. Over the past four years, we ordered approximately one billion base pairs of synthetic DNA from Twist, allowing us to test hundreds of thousands of proteins across dozens of programs for our customers, resulting in many completed programs spanning vaccine manufacturing, food, flavor, fragrance and even cannabigerol (CBG),” said Jason Kelly, CEO of Ginkgo. “As we grow our capabilities to meet an increasing number and variety of customer needs, we are excited to continue partnering with leading companies in our ecosystem, which includes making sure we secure the high volumes of DNA that Twist is well positioned to supply.”

“At Twist, we work in service of our customers, like Ginkgo, who are changing the world for the better,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “Together, Twist and Ginkgo facilitate new product development across multiple industries, with Twist supplying the DNA and Ginkgo programming cells. As the bioeconomy expands with new solutions to the grand challenges facing all of us, we stand ready to deliver day by day, with a vision as to how as an industry, we can truly drive positive outcomes through diverse product solutions.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more